Pfizer Inc
NYSE: PFE
$25.83
+$0.06 (+0.2%)
Closing Price on November 27, 2024
PFE Articles
Nestle to buy Pfizer’s (NYSE: PFE) baby food operation for $11.9 billion. (Reuters) China’s factory output rises slightly in March, but still not at levels of expansion. (Reuters) Vodafone...
Published:
Pfizer (NYSE: PFE) wanted out of the baby nutrition business and found a ready buyer for the division that owns its operations in that industry. There has been a rumor that Nestle has wanted the...
Published:
Citigroup (NYSE: C) losses an investor vote on executive compensation. (Reuters) Many experts say Spain cannot avoid a bailout. (Reuters) Nestle is close to a deal to buy Pfizer’s (NYSE: PFE) baby...
Published:
The CEO of Chrysler said he took no pay in 2011 and that, based on financial results, the company is now worth $7.5 billion. (Reuters) The Treasury will sell $6 billion of AIG (NYSE: AIG) stock to...
Published:
Anheuser-Busch InBev NV may buy China’s Kingway Brewery Holdings’ assets. (Reuters) The Department of Justice is expected to widen its probe of mortgage-backed securities. (Reuters) AT&T...
Published:
Glencore and Xstrata are in merger talks. (Reuters) A federal mortgage deal with banks over mortgage fraud would give states enforcement power. (Reuters) Sony (NYSE: SNE) expects a $2.9 billion...
Published:
All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to meet expectations and came in lower even than last month’s reading. The lower...
Published:
Last Updated:
Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s guidance may be getting in the way a bit. The drug giant turned in results of...
Published:
Last Updated:
Tuesday is going to be full of major earnings reports, two of which are DJIA components. These are not the only major earnings, but ten we will be watching closely are as follows: Amazon.com Inc....
Published:
Last Updated:
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to their...
Published:
Last Updated: